PEPTRON, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30,750 KRW | +1.15% |
|
+6.03% | -23.60% |
| 2023 | Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal | MT |
| 2023 | Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023. | CI |
ETFs positioned on Peptron, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.45% | - |
Peptron, Inc. is a Korea-based company principally engaged in the development, manufacture and distribution of sustained-release medications. The Company mainly produces peptides as drug materials mainly for prostate cancer, hyperpituitarism, diabetes and neurodegenerative disorders. The Company also provides peptide synthesis services. The Company manufactures raw material medicines and some functional cosmetics. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -23.60% | 465M | |
| +2.93% | 108B | |
| +8.82% | 105B | |
| +1.11% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B |
- Stock Market
- Equities
- A087010 Stock
- Funds and ETFs Peptron, Inc.